Abstracts tagged "Systemic lupus erythematosus (SLE)"

Abstract Number: 1059 • ACR Convergence 2024
The Negative Impact of Physicians’ Neuroticism and Conscientiousness on Shared Decision Making in Patients with Systemic Lupus Erythematosus: The TRUMP2-SLE Project
Shigemi Morishita¹, Kenei Sada², Masataka Kudo³, Naofumi Dobashi⁴, Ryusuke Yoshimi⁵, Natsuki Sakurai⁶, Chiharu Hidekawa⁶, Yasuhiro Shimojima⁷, Dai Kishida⁷, Takanori Ichikawa⁷, Yoshi Miyawaki⁸, Keigo Hayashi⁹, Kenta Shidahara¹⁰, Yuichi Ishikawa¹¹, Nao Oguro¹², Nobuyuki Yajima¹³ and Noriaki Kurita¹⁴, ¹Department of Surgery, Oida Hospital, Sukumo, Japan, ²Department of Clinical Epidemiology, Kochi Medical School, Kochi University, Nankoku, Kochi, Japan, ³Department of General Internal Medicine, Iizuka Hospital, Fukuoka, Japan, ⁴Department of Internal Medicine, Kochi Prefectural Hata-Kenmin Hospital, Sukumo, Japan, ⁵Department of Medicine (Neurology and Rheumatology), Shinshu University School of Medicine, Yokohama, Kanagawa, Japan, ⁶Department of Stem Cell and Immune Regulation,Yokohama City University Graduate School of Medicine, Yokohama, Kanagawa, Japan, ⁷Department of Medicine (Neurology and Rheumatology), Shinshu University School of Medicine, Matsumoto, Nagano, Japan, ⁸Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan, ⁹Brigham and Women’s Hospital, Brookline, MA, ¹⁰"Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Okayama, Japan, ¹¹The First Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Fukuoka, Japan, ¹²Division of Rheumatology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan, ¹³Division of Rheumatology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan., Tokyo, Japan, ¹⁴Department of Clinical Epidemiology, Graduate School of Medicine, Fukushima Medical University, Fukushima, Japan
Background/Purpose: The treatment of systemic lupus erythematosus (SLE) remains challenging due to its complexity, despite the introduction of various promising treatments. Recent EULAR recommendations emphasize…
Abstract Number: 1266 • ACR Convergence 2024
Anti-Mitochondrial Antibodies Associate with Disease Activity and IFNα Expression in Childhood-onset Systemic Lupus Erythematosus
Marina Barguil Macedo¹, Javad Wahadat², Albin Bjoerk³, Sylvia Kamphuis², Marjan Versnel² and Christian Lood¹, ¹University of Washington, Seattle, WA, ²Erasmus University Medical Center, Rotterdam, Netherlands, ³Karolinska Institutet, Stockholm, Sweden
Background/Purpose: Extracellular mitochondria may represent a source of antigenic burden in autoimmune disorders, such as in systemic lupus erythematosus (SLE), in which those organelles, released…
Abstract Number: 1485 • ACR Convergence 2024
Genetic Contributions to Systemic Lupus Erythematosus: Concordance Rates in California Twins
Rashmi Dhital¹, Jia Yin Wan², Kenneth Kalunian³ and Wendy Cozen⁴, ¹UC San Diego, Brentwood, TN, ²Samueli School of Public Health, University of California Irvine, Irvine, CA, ³University of California San Diego, La Jolla, CA, ⁴University of California Irvine, Irvine
Background/Purpose: Systemic lupus erythematosus (SLE) is influenced by both genetic and environmental factors. Twin studies in SLE have shown varying levels of concordance. This study…
Abstract Number: 1502 • ACR Convergence 2024
The Systemic Lupus International Collaborating Clinics (SLICC) Frailty Index (SLICC-FI) Predicts Hospitalizations. Data from the Almenara Lupus Cohort
Manuel Ugarte-Gil¹, RV, Gamboa-Cardenas², Victor Pimentel-Quiroz³, Cristina Reategui⁴, Claudia Elera Fitzcarrald⁵, Cesar Pastor-Asurza⁶, Zoila Rodriguez-Bellido⁶, Risto Perich-Campos⁶ and Graciela Alarcon⁷, ¹Universidad Cientifica del Sur, Lima, Lima, Peru, ²Universidad Científica del Sur, Lima, Lima, Peru, ³Universidad Científica del Sur/Hospital Nacional Guillermo Almenara Irigoyen, Magdalena del Mar, Peru, ⁴Servicio de Reumatología. Hospital Nacional Guillermo Almenara Irigoyen, EsSalud/Grupo Peruano de Estudio de Enfermedades Autoinmunes Sistémicas, Universidad Científica del Sur, Lima, Lima, Peru, ⁵Hospital Nacional Guillermo Almenara Irigoyen/Universidad San Ignacio de Loyola, Lima, Peru, ⁶Hospital Nacional Guillermo Almenara Irigoyen, Lima, Lima, Peru, ⁷The University of Alabama at Birmingham, Oakland, CA
Background/Purpose: Frailty, measured with the SLICC-FI, has been reported as a predictor of damage in several cohorts. The aim of this study is to evaluate…
Abstract Number: 1518 • ACR Convergence 2024
Predictive Value of Chronic Histologic Changes in Lupus Nephritis
Maria Cuellar-Gutierrez¹, Jaime Flores Gouyonnet¹, Gabriel Figueroa-Parra², Marta Casal Moura¹, Fernando C. Fervenza¹, Andrew C. Hanson³, Cynthia Crowson¹, Sanjeev Sethi¹ and Ali Duarte-Garcia¹, ¹Mayo Clinic, Rochester, MN, ²Division of Rheumatology, University Hospital "Dr. Jose Eleuterio Gonzalez", Universidad Autonoma de Nuevo Leon, Monterrey, Mexico, ³Mayo Clinic, Rochester
Background/Purpose: We aimed to assess the predictive value of the individual components of the NIH chronicity score and the Mayo Clinic Chronicity Score (MCCS) in…
Abstract Number: 1535 • ACR Convergence 2024
Variations in Tacrolimus Whole Blood Concentrations During Pregnancy and Its Implications for Therapeutic Drug Monitoring: A Systematic Review and Meta-analysis
Reem Farhat¹, Arielle Mendel², Isabelle Malhamé², Ami Grunbaum³, Sasha Bernatsky⁴ and Evelyne Vinet², ¹McGill University, Montreal, QC, Canada, ²McGill University Health Centre, Montreal, QC, Canada, ³Research Institute of the McGill University Health Centre, Montréal, QC, Canada, ⁴Research Institute of the McGill University Health Centre, Montreal, QC, Canada
Background/Purpose: Tacrolimus is a pregnancy-compatible immunosuppressive increasingly used in systemic lupus erythematosus (SLE) pregnancies. Physiological changes throughout pregnancy impact tacrolimus pharmacokinetics, altering the drug’s whole…
Abstract Number: 1555 • ACR Convergence 2024
Sustained Functional Assessment of Chronic Illness Therapy–Fatigue Response in Patients with SLE Receiving Anifrolumab Alongside Standard Therapy
Vibeke Strand¹, Kenneth Kalunian², Ian Bruce³, Caroline Seo⁴, Kai Wai Lee⁵, Jacob Knagenhjelm⁶ and Catharina Lindholm⁶, ¹Division of Immunology/Rheumatology, Stanford University, Palo Alto, CA, ²University of California San Diego, La Jolla, CA, ³Centre for Musculoskeletal Research, The University of Manchester, Manchester, United Kingdom, ⁴BioPharmaceuticals Medical Evidence, AstraZeneca, Gaithersburg, MD, ⁵Biopharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom, ⁶BioPharmaceuticals Medical, AstraZeneca, Gothenburg, Sweden
Background/Purpose: Fatigue is highly prevalent and severely affects health-related quality of life (HRQoL) in patients with SLE.1,2 We previously demonstrated that, compared with placebo, a…
Abstract Number: 1749 • ACR Convergence 2024
Safety and Long-term Efficacy of CD19-CAR T-cell Therapy in 30 Patients with Autoimmune Disease
Melanie Hagen¹, Fabian Müller², Andreas Wirsching¹, Carlo Tur¹, Tobias Krickau³, Markus Metzler⁴, Laura Bucci¹, Christina Bergmann⁵, Janina Auth¹, Jule Taubmann⁶, Panagiotis Garantziotis⁷, Sebastian Boeltz⁸, Soraya Kharboutli⁹, Silvia Spoerl⁹, Simon Völkl¹⁰, Michael Aigner⁹, Sascha Kretschmann⁹, Ingrid Vasova⁹, Andreas MAckensen¹¹, Ricardo Grieshaber-Bouyer⁸ and Georg Schett¹², ¹Department of Medicine 3 - Rheumatology and Immunology, Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg and Uniklinikum Erlangen, Erlangen, Bayern, Germany, ²Department of Medicine 5 - Hematology and Oncology, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU) and Uniklinikum Erlangen, Erlangen, Germany, ³Department of Pediatrics and Adolscent Medicine, Friedrich-Alexander-Universität Erlangen-Nürnberg and University Hospital Erlangen, Erlangen, Bayern, Germany, ⁴Department of Pediatrics and Adolscent Medicine, Friedrich-Alexander-Universität Erlangen-Nürnberg and University Hospital Erlangen, Erlangen, Germany, ⁵Department Internal Medicine III, Friedrich-Alexander-University (FAU) Erlangen-Nurnber, Frankfurt, Germany, ⁶Friedrich-Alexander Universität Erlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany, ⁷Department of Internal Medicine 3-Rheumatology and Immunology, Friedrich Alexander University Erlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany, Erlangen, Germany, ⁸Department of Medicine 3 - Rheumatology and Immunology, Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg and Uniklinikum Erlangen, Erlangen, Germany, ⁹Department of Medicine 5 - Hematology and Oncology, Friedrich-Alexander-Universität Erlangen-Nürnberg and University Hospital Erlangen, Erlangen, Germany, ¹⁰Department of Medicine 5 - Hematology and Oncology, Friedrich-Alexander-Universität Erlangen-Nürnberg and University Hospital Erlangen, Erlangen, Bayern, Germany, ¹¹Department of Medicine 5 - Hematology and Oncology, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU) and Uniklinikum Erlangen, Erlangen, Bayern, Germany, ¹²Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany
Background/Purpose: Treating autoimmune diseases like Systemic Lupus erythematosus (SLE), Idiopathic Inflammatory Myositis (IIM) or Systemic Sclerosis (SSc) is challenging and often requires life-long immunosuppressive therapy.…
Abstract Number: 1789 • ACR Convergence 2024
Multi-omic Profiling Identifies Pathogenic Pro-inflammatory Human Monocytes/Macrophages in Systemic Lupus Erythematosus
Lais Osmani¹, Min Shin², Sang Jin Lee³, Helen Cai⁴, Won Jae Seong², Hyoungsu Kim², Jongjin Yoo², Angela Mirabella², William Bracamonte², Mario Felix⁵, Jong Gyun Ahn², Hong-Jai Park², Juan Young⁶, Junghee Shin², Serhan Unlu⁷, Noelle Yoo², Edward Doherty², Jiaye Chen², Chenxi Li², Gabriela Sanchez-Zuno², Caroline Valdez⁴, Thuy Tran⁸, Mei Dong², Sang Kim², Christine Ko⁹, Sungyong You¹⁰, Jose Gomez¹¹, Richard Bucala¹² and Insoo Kang², ¹Yale, New Haven, CT, ²Yale University School of Medicine, Internal Medicine (Rheumatology, Allergy & Immunology), New Haven, CT, ³Division of Rheumatology, Kyungpook National University Hospital, Dae gu, Republic of Korea, ⁴Yale University School of Medicine, New Haven, CT, ⁵Yale, Hamden, CT, ⁶Yale University School of Medicine, Psychiatry, New Haven, CT, ⁷Cleveland Clinic, Internal Medicine, Cleveland, OH, ⁸Yale University School of Medicine, Internal Medicine (Medical Oncology), New Haven, CT, ⁹Yale University School of Medicine, Dermatology and Pathology, New Haven, CT, ¹⁰Cedars-Sinai Medical Center, Surgery and Computational Biomedicine, Los Angeles, CA, ¹¹Yale University School of Medicine, Internal Medicine (Pulmonary, Critical Care & Sleep), New Haven, CT, ¹²Yale University School of Medicine, Internal Medicine (Rheumatology, Allergy & Immunology) and Pathology, New Haven, CT
Background/Purpose: Systemic lupus erythematosus (SLE or lupus) is a clinically heterogeneous autoimmune disease, in which emerging evidence implicates the innate immune system, particularly monocytes and…
Abstract Number: 1809 • ACR Convergence 2024
Melanocytes Are Driven Toward an Antigen Presentation Phenotype Through UV-Induced Keratinocyte Crosstalk and Exposure to Type I Interferons in Patients with Cutaneous Lupus Erythematosus
Rezvan Moallemian, Lin Zhang, Mehrnaz Gharaee-Kermani, Allison Billi, Amy Hurst, Benjamin Klein and J. Michelle Kahlenberg, University of Michigan, Ann Arbor, MI
Background/Purpose: Cutaneous lupus erythematosus (CLE) encompasses various lesion morphologies, but photosensitivity and high type I interferon (IFN) responses are a unifying theme amongst all CLE…
Abstract Number: 1961 • ACR Convergence 2024
Salivary and Lacrimal Glands Ultrasonography in Systemic Lupus Erythematosus Patients
Mohammadrafi Damirchi¹, Nafiseh Abdolahi², Fatemeh Hosseini³, Mohadeseh Mohammadi³, Mina Khosravi⁴, Zahra Niakan¹ and Siavash Abbasi³, ¹Golestan Rheumatology Research Center, Golestan University of Medical Sciences, Gorgan, Iran, Gorgan, Iran, ²Golestan Rheumatology Research Center, Golestan University of Medical Sciences, Gorgan, Iran, Melbourne, Australia, ³Department of Radiology, Golestan University of Medical Sciences, Gorgan, Iran, Gorgan, Iran, ⁴Faculty of Medicine, Iran University of Medical Sciences, Tehran, Iran, Tehran, Iran
Background/Purpose: Systemic Lupus Erythematosus (SLE) is an autoimmune inflammatory condition that can manifest in various ways, such as oral and eye-related symptoms, which may overlap…
Abstract Number: 2373 • ACR Convergence 2024
The Construction and Validation of Sub-phenotype-specific Genetic Risk Scores in Systemic Lupus Erythematosus: A Novel Approach Using Large-scale Biobank Data
Sarah Reid¹, Johanna Sandling², Pascal Pucholt³, Ahmed Sayadi⁴, Martina Frodlund⁵, Karoline Lerang⁶, Andreas Jönsen⁷, Christopher Sjowall⁸, Iva Gunnarsson⁹, Ann-Christine Syvänen², Anders Bengtsson⁷, Øyvind Molberg¹⁰, Elisabet Svenungsson¹¹, Anna Rudin¹², Solbritt Rantapaa-Dahlqvist¹³, Lars Rönnblom² and Dag Leonard², ¹Uppsala University, Medical Sciences, Uppsala, Sweden, ²Uppsala University, Uppsala, Sweden, ³Rheumatology and Science for Life Laboratory, Department of Medical Sciences, Uppsala university, Uppsala, Sweden, ⁴Uppsala, Uppsala, Sweden, ⁵Department of Biomedical and Clinical Sciences, Division of Inflammation and Infection/Rheumatology, Linköping University, Linköping, Sweden, ⁶Oslo University Hospital, Oslo, Norway, ⁷Lund University, Lund, Sweden, ⁸Linköping University, Linköping, Sweden, ⁹Karolinska Institute, Stockholm, Sweden, ¹⁰Oslo University Hospital, Department of Rheumatology, Oslo, Nepal, ¹¹Karolinska Institutet, Stockholm, Sweden, ¹²Institute of Medicine, University of Gothenburg, Gothenburg, Sweden, ¹³Umeå University, Umeå, Sweden
Background/Purpose: Systemic lupus erythematosus (SLE) is an autoimmune disease with a heterogeneous clinical picture. This study aimed to link genetic SLE predisposition with relevant clinical…
Abstract Number: 2391 • ACR Convergence 2024
Identification of Patients with ANA Negative and Double Stranded DNA Positive: What Is the Significance in Daily Rheumatology Practise
Güllü Sandal Uzun¹, Emily Apsley² and David Isenberg², ¹University College London, London, England, United Kingdom, ²University College London, London, United Kingdom
Background/Purpose: The anti-nuclear antibody (ANA test) is a sensitive screening tool used when assessing patients with possible autoimmune rheumatic diseases (ARD). Homogeneous staining positivity is…
Abstract Number: 2410 • ACR Convergence 2024
A Novel Treatment Response Measure for SLE Clinical Trials (TRM-SLE): Selection of Domains and Candidate Measures
Kathryn Connelly¹, Rachel Koelmeyer¹, Darshini Ayton¹, Lavanya Rajagopala², Ambika Wahklu², John May³, Raychel Barallon⁴, Rangi Kandane-Rathnayake⁵, Laura Eades¹, kate Gregory¹ and Eric Morand⁶, and the TRM-SLE Taskforce, ¹Monash University, Melbourne, Victoria, Australia, ²Monash Health, Melbourne, Victoria, Australia, ³Monash Medical Centre, Richmond, Victoria, Australia, ⁴Monash Health, Clayton, Victoria, Australia, ⁵Monash University, Clayton, Victoria, Australia, ⁶School of Clinical Sciences, Monash University, Melbourne, Victoria, Australia
Background/Purpose: The success of randomised controlled trials (RCTs) in SLE has been hampered by limitations of current outcome measures, contributing to negative or discordant trial…
Abstract Number: 2426 • ACR Convergence 2024
Multi-OMICs Analysis Including Lipidomics to Correlate Baseline OMICs Profiles with Disease Activity and Response to Different Immunomodulatory Treatments in Patients with Systemic Lupus Erythematosus – An Exploratory Pilot Study Using a Multi-OMICs Approach
Michaela Koehm¹, Samuel Rischke², Robert Gurke³, Gerd Geißlinger⁴ and Frank Behrens¹, ¹University Hospital Goethe University Frankfurt and Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Frankfurt, Germany, ²Goethe University Frankfurt, Institute of Clinical Pharmacology, Frankfurt, Germany, ³Goethe University Frankfurt, Institute of Clinical Pharmacology and Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Frankfurt, ⁴Goethe University Frankfurt, Institute of Clinical Pharmacology and Fraunhofer Insitute for Translational Medicine and Pharmacology ITMP, Frankfurt
Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic autoimmune disease with a very heterogeneous clinical presentation and severity. Despite the variety of treatment options available,…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].